The above studies suggest that mutations in the EGFR gene are associated with diminished PD-L1 expression, whereas higher incidences of PD-L1 positivity are observed in NSCLC patients harboring ALK or ROS1 rearrangements (31–33). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.